Prolonged follow‐up on lenalidomide‐based treatment for mucosa‐associated lymphoid tissue lymphoma (MALT lymphoma)—Real‐world data from the Medical University of Vienna

Based on results of two pilot trials, lenalidomide (LEN) was found to be active and safe as monotherapy and showed an increased response rate of 80% in combination with rituximab (R) for patients with mucosa‐associated lymphoid tissue (MALT) lymphoma. While initial results were promising, there are...

Descripción completa

Detalles Bibliográficos
Autores principales: Kiesewetter, Barbara, Lamm, Wolfgang, Neuper, Ortrun, Mayerhoefer, Marius E., Simonitsch‐Klupp, Ingrid, Raderer, Markus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6899635/
https://www.ncbi.nlm.nih.gov/pubmed/31283840
http://dx.doi.org/10.1002/hon.2647

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6899635/
https://www.ncbi.nlm.nih.gov/pubmed/31283840
http://dx.doi.org/10.1002/hon.2647

Ejemplares similares